Modified Citrus Pectin (MCP): The Anti-Metastatic Supplement? Evidence, Benefits and Research - Dr Paul Marik

By Editorial Team

Last updated: July 2026

Introduction

Modified citrus pectin (MCP) is a low-molecular-weight form of citrus pectin designed for absorption. It has attracted attention because laboratory research suggests it may bind galectin-3, a protein involved in inflammation, fibrosis, immune regulation and cancer metastasis. Although preclinical evidence is encouraging, human clinical evidence remains limited and MCP should not be considered a proven cancer treatment.

What is Modified Citrus Pectin?

MCP is produced by altering natural citrus pectin into smaller fragments that are more readily absorbed than ordinary dietary pectin.

Galectin-3 and Cancer

Galectin‑3 is a β‑galactoside–binding lectin implicated in tumor cell aggregation, adhesion, angiogenesis, apoptosis resistance, immune evasion, and organ fibrosis.(2)
  • Cell adhesion
  • Tumor invasion
  • Metastasis
  • Angiogenesis
  • Immune evasion

How MCP May Work

  • May interfere with galectin-3 mediated cell adhesion.
  • May reduce metastatic spread in experimental models.
  • May influence immune activity and fibrosis.
  • May complement—not replace—standard oncology care.

Human Evidence

Small clinical studies, particularly in prostate cancer, suggest possible slowing of PSA doubling time in some patients. However, large randomized trials demonstrating improved survival or prevention of metastasis are lacking.

Modified citrus pectin (MCP) has the most human data in prostate cancer (biochemically relapsed, non‑metastatic), with additional preclinical data across several other tumor types including melanoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, multiple myeloma, and hemangiosarcoma. (2)

Prostate cancer

  • A prospective phase II study of P‑MCP in 60 men with non‑metastatic biochemical relapse (rising PSA after local therapy) used 4.8 g three times daily for 6 months; 58 completed at least one month.​(6)

  • MCP treatment was associated with lengthening of PSA‑doubling time in a significant subset and lower‑than‑expected rates of progression versus historical controls, with minimal toxicity, leading authors to conclude MCP “has a potential benefit and is safe” in this setting and warrants further trials.​

  • Prior smaller pilot studies also suggested PSA‑DT prolongation in men with biochemical recurrence, which prompted a phase III trial (NCT01681823) evaluating MCP effects on PSA kinetics; full phase III outcome data are still limited/unclear in the public domain.

Advanced solid tumors

  • A 49‑patient pilot study in advanced solid tumors treated with modified (hydrolyzed) citrus pectin reported good tolerability, disease stabilization in a subset, and occasional minor responses, but no randomized control; it was framed as exploratory for safety and “clinical benefit” rather than definitive efficacy.​(7) The study was summarized as follows: “MCP seems to have positive impacts especially regarding clinical benefit and life quality for patients with far advanced solid tumors. The presented preliminary data encourages us to further investigate the role of MCP in cancer prevention and treatment.”

  • Overall, human oncology data remain early‑phase, with signals in biochemical recurrence prostate cancer and disease stabilization in mixed solid tumors, but no robust survival or hard endpoint data yet. ClinicalTrials.gov ID NCT01681823

Cancers with preclinical evidence

Most other “signals” are preclinical (in vitro and animal models), often via galectin‑3 inhibition (adhesion, apoptosis, angiogenesis, metastasis).(8)

  • Melanoma – Experimental metastasis models showed MCP reduced melanoma spread.​(2)

  • Breast cancer – MCP inhibited invasion and metastasis of metastatic breast carcinoma cells, and reduced angiogenesis in mouse models.​(2)

  • Colon/colorectal cancer – MCP and other modified pectins show antiproliferative and pro‑apoptotic effects in colorectal cancer models, with some data on reduced tumor burden in animals.(9)

  • Ovarian cancer – PectaSol‑C MCP inhibits galectin‑3–induced STAT3 activation and synergizes with paclitaxel in SKOV‑3 multicellular spheroid models.(10)

  • Bladder (urothelial) cancer – MCP reduced proliferation, induced cell‑cycle arrest and apoptosis, and significantly inhibited T24 xenograft growth in mice via galectin‑3–dependent mechanisms.​(8)

  • Multiple myeloma – MCP reversed galectin‑3–mediated resistance to bortezomib and enhanced dexamethasone‑induced apoptosis in myeloma cells.​(2)

  • Hemangiosarcoma and endothelial tumors – MCP reduced clonogenic survival, increased sensitivity to doxorubicin, and inhibited angiogenesis and spontaneous metastasis in mouse models.​(2)

Safety and tolerability

  • Across oncology and cardiovascular trials, MCP has been generally well tolerated at doses around 4.8–15 g/day, with adverse events mostly limited to mild GI symptoms (bloating, loose stools, nausea).(7)

  • No significant hepatotoxicity, nephrotoxicity, or myelosuppression has been observed in published clinical trials, and phase II prostate data report “no significant toxicity,” but long‑term safety beyond 1–2 years is not well characterized.(11)

Regulatory and guideline status

  • MCP is marketed as a dietary supplement rather than an approved drug; there is no major oncology guideline (e.g. NCCN, ESMO) endorsement for its use as standard cancer therapy, and patient information resources like Cancer Research UK describe the evidence as “very early” and experimental.​

  • ClinicalTrials.gov lists several completed and ongoing studies, mostly in prostate cancer and cardiometabolic contexts, underscoring its status as an investigational adjunct rather than a validated treatment.

Practical considerations (oncology context)

  • Typical research doses in prostate BRPC: 4.8 g TID of a defined MCP product (e.g., PectaSol‑C), taken away from food to improve absorption, for 6–12 months or until progression.

  • From a risk–benefit standpoint, in a patient interested in integrative approaches, MCP could be considered a low‑toxicity experimental adjunct in BRPC or advanced solid tumors, with counseling that evidence is limited, endpoints are largely surrogate (PSA, stabilization), and it should not replace effective standard therapies.

Timing of administration

This is very problematic as MCP interferes with the absorption of several drugs, minerals and nutraceuticals and food interferes with the absorption of MCP.

Modified citrus pectin (MCP) can interfere with the absorption of certain medications and nutrients, though the extent varies depending on timing and dosage. Pectin molecules contain negatively charged carbohydrate structures that can bind or complex with other compounds in the intestinal lumen. The concern is that MCP could bind drugs, minerals, or other supplements and reduce the free fraction available for absorption. Furthermore, soluble fibers can increase intestinal viscosity. Even modest gel-like behavior may slow movement of drugs toward the intestinal wall. This can delay or reduce absorption, especially for drugs that already have limited bioavailability. Reviews of plant fibers and bile-acid interactions describe viscosity and impaired micellar mobility as key mechanisms by which fibers influence intestinal absorption.

MCP can reduce absorption of several medications by 20-40%, particularly affecting:

  • minerals such as iron, zinc, magnesium, calcium

  • thyroid hormone

  • antibiotics, especially tetracycline antibiotics

  • oral chemotherapy or targeted drugs

  • digoxin (Lanoxin)

  • narrow-therapeutic-index drugs

  • statins

  • blood pressure medications such as ACE and ARB’s

Clinical implication

  • MCP behaves pharmacokinetically like a soluble fiber: its main interaction is binding and reducing absorption, not CYP-mediated metabolism effects.

  • Extra caution is warranted with narrow-therapeutic-index agents (e.g., digoxin) and critical antibiotics, where even modest reductions in exposure may matter clinically.

  • For polypharmacy, a simple rule is to treat MCP like a “gut binder”: schedule it away from morning and evening medication clusters by at least 1–2 hours when feasible.

Table 1. Suggested time separation between various medications and MCP


Practical Clinical Considerations

The fiber content of MCP is responsible for most absorption interference, as it can bind to substances in the digestive tract. To minimize interactions, separate MCP administration from other medications and supplements by 2-4 hours. Since repurposed drugs and nutraceutical combinations are the primary intervention for cancer patients, timing protocols become critically important when combining MCP with other repurposed drugs or supplements.

The best time to take MCP is 30 minutes before a meal or 2 hours after eating on an empty stomach, while maintaining at least a 2-hour buffer from all medications and mineral supplement. The best approach may be to anchor MCP in a consistent mid-morning or mid-afternoon slot to avoid medication “clusters” typically taken at breakfast and bedtime. Maintain consistent daily timing.

It is unfortunate that this critical information is not printed on the medication label nor the manufacturers website.

Table 2. Level of evidence summary by type of cancer

FAQ

Can MCP cure cancer?

There is currently no high-quality evidence showing MCP cures cancer.

Can it reduce metastasis?

Laboratory evidence suggests anti-metastatic potential, but definitive human evidence is still insufficient.


Medical Disclaimer

This article is for educational purposes only and is not medical advice. 


Primary Source for This Review

References

1. Leclere L, Cutsem PV, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. Front Pharmacol. 2013;4:128.

2. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788–91.

3. García-Revilla J, Boza-Serrano A, Espinosa-Oliva AM, Soto MS, Deierborg T, Ruiz R, et al. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 2022;13(7):628.

4. Ismail R, Habib HA, Anter AF, Amin A, Heeba GH. Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways. Front Pharmacol. 2025;16:1528978.

5. Kassab AE. The Most recent updates on pectin in Cancer therapy: A review. Int J Biol Macromol. 2025;326:147331.

6. Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, et al. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 2021;13(12).

7. Azemar M, Hildenbrand B, Haering B, Heim ME, Unger C. Clinical Benefi t in Patients with Advanced Solid Tumors Treated with Modifi ed Citrus Pectin: A Prospective Pilot Study. Clinical Medicine Oncology. 2007;1:73–80.

8. Fang T, Liu DD, Ning HM, Dan L, Sun JY, Huang XJ, et al. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin. 2018;39(12):1885–93.

9. Ornelas AC, Ferguson S, DePlaza M, Adekunle T, Basha R. Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment. Onco Ther. 2022;9(2):43–55.

10. Hossein G, Halvaei S, Heidarian Y, Dehghani-Ghobadi Z, Hassani M, Hosseini H, et al. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 2019;8(9):4315–29.

11. Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, et al. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021;6(1):12–21.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Com...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Ivermectin combined with benzimidazoles (fenbendazole, mebendazole) represents an emerging area of repurposed oncology pharmacology. All protocols require physician supervision. Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dos...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Medically Reviewed | Last updated on May 30, 2026. Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fe...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...
Read more